Skip to content
Clinical Trials – home
Therapeutic area

Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 156

  • 3 898 clinical trials
  • 1 548 recruiting
  • 703 conditions
  • 31 countries

Conditions in this area

703 conditions with trials, the busiest first

Clinical trials in Neoplasms benign, malignant and unspecified (incl cysts and polyps)

3 898 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

3 898 clinical trials

Glioma

Not yet recruiting

Study on Using [68Ga]NOTA-AE105 to Visualize and Differentiate Gliomas in Patients

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:[68GA]GA-NOTA-AE105
  • Sponsor:Rigshospitalet

Breast cancer in situ

Not yet recruiting

Study on Detecting and Classifying Breast Disease Using Iodixanol in Digital Mammography and Tomosynthesis Compared to MRI in Patients with Breast Pathology

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Iodixanol
  • Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale

Plasma cell myeloma

Not yet recruiting

Study on Treating Smoldering and Active Multiple Myeloma with Dexamethasone, Lenalidomide, and Carfilzomib for Patients in Iceland

Registered drugNo placebo
Countries:IcelandIceland
  • Participants:18–64 years
  • Substances:Carfilzomib
  • Sponsor:Landspitali

Study on Alectinib for Patients with ALK+ Stage III Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Alectinib
  • Sponsor:GOIRC Gruppo Oncologico Italiano Di Ricerca Clinica

Ewing's sarcoma

Not yet recruiting

Study on Treosulfan and Melphalan for High-Risk Ewing Sarcoma Patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Cyclophosphamide
  • Sponsor:Fondazione Santobono Pausilipon Onlus

Pancreatic carcinoma

Not yet recruiting

Study on the Effects of Rintatolimod After FOLFIRINOX in Patients with Locally Advanced Pancreatic Cancer

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Rintatolimod
  • Sponsor:Aim Immunotech Inc.

Study of Ipilimumab and Nivolumab with or without Radiotherapy for Patients with Melanoma Brain Metastases

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:Melanoma Institute Australia

Diffuse large B-cell lymphoma+7

Not yet recruiting

Study on the Effectiveness and Safety of Cytarabine, Tafasitamab, and Lenalidomide for Patients with Relapsed Diffuse Large B-Cell Lymphoma

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Instytut Hematologii I Transfuzjologii

Acute myeloid leukaemia

Not yet recruiting

Study on WT1-loaded CBDC Vaccine for Children and Young Adults with Acute Myeloid Leukemia

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years
  • Substances:Autologous Cord Blood-Derived Dendritic Cells Loaded With Wt1 Peptide Pool
  • Sponsor:Princess Maxima Center For Pediatric Oncology

Neoplasm

Not yet recruiting

Study on Pembrolizumab, Atezolizumab, and Nivolumab with Carbon Ion Radiotherapy for Patients with Advanced Melanoma, Urothelial Carcinoma, NSCLC, or Head & Neck Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Fondazione Centro Nazionale Di Adroterapia Oncologica

Acute myeloid leukaemia

Not yet recruiting

Study on the Safety and Effects of AB8939 and Azacitidine for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Ab Science

Transitional cell carcinoma

Not yet recruiting

Study of Durvalumab Combined with Chemotherapy (Gemcitabine/Cisplatin or Gemcitabine/Carboplatin) for Patients with High-Risk Upper Urinary Tract Cancer Before Surgery

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Centre Hospitalier Universitaire De Nimes

Substances studied in this area

The therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.